Proactive Investors - Run By Investors For Investors

Summit Therapeutics expands enrolment in Phase 2 PhaseOut DMD trial

Summit is extending an invitation to DMD sufferers who participated in the Phase 1 trial of ezutromid but who were not initially eligible for the Phase II trial to get back in the programme
Small boy crying on the stairs
Patients are eligible to participate regardless of their ambulatory status or age.

Summit Therapeutics PLC (NASDAQ:SMMT, LON:SUMM) has opened enrolment in a planned additional group in its Phase 2 open-label clinical trial called PhaseOut DMD.

PhaseOut DMD is a trial of ezutromid, Summit's drug candidate for the treatment of Duchenne Muscular Dystrophy, a rare muscle-wasting disease that affects boys and young men.

READ: Summit Therapeutics shares jump as initial results of clinical trial for Duchenne muscular dystrophy treatment shows "further positive findings"

Enrolment is open to patients who participated in Phase 1 clinical trials of ezutromid but who did not meet the entry criteria for the main PhaseOut DMD cohorts.

Study assessments will include functional tests appropriate for the patient's ambulatory status, cardiac magnetic resonance imaging (MRI) and lung function tests.

"We are extremely grateful to the patients who participated in our Phase 1 clinical trials and contributed to ezutromid's clinical advancement, but were not initially eligible to participate in our Phase 2 clinical trial. Accordingly, we are pleased to open this additional group in our Phase 2 and provide these patients with the opportunity to receive ezutromid treatment," said Dr David Roblin, the chief operating officer and medical officer of Summit. 

"We expect the data collected from this additional group of patients will help expand our understanding of ezutromid's safety and efficacy profile across a broader patient population," he added.

Shares in Summit were up a penny at 181p in lunchtime trading.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use